Skip to content
CFPS Research Archives

Nemifitide

Human clinical Cognitive Enhancement 3 sources

Nemifitide (INN-00835) is a novel synthetic pentapeptide analog of melanocyte-inhibiting factor (MIF-1). Research indicates it may possess rapid-acting antidepressant properties, showing efficacy in clinical trials for major depressive disorder within days rather than weeks.

01Dosing reference

Amount
30-45 mg/day
Frequency
Once daily
Cycle
5-14 days in acute clinical trial settings
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

MIF-1 Receptor Modulation

Acts as an analog to the endogenous peptide melanocyte-inhibiting factor (MIF-1) in the central nervous system.

02

Neurotransmitter Regulation

Modulates dopaminergic and other neurotransmitter pathways, though the exact receptor binding profile remains partially characterized.

03

Rapid Antidepressant Effect

Leads to a rapid alleviation of depressive symptoms, bypassing the typical delayed onset seen with traditional monoaminergic antidepressants.

03Human evidence

Significant response to treatment after 5 days of dosing.

Evaluated using psychometric tests in depressed outpatients, demonstrating rapid onset of action.

Efficacy in the treatment of major depressive disorder (MDD).

Evaluated in randomized, placebo-controlled clinical trials comparing 30 mg/d and 45 mg/d dosages.

04Preclinical evidence

Antidepressant-like effects in animal models.

Demonstrated efficacy in the olfactory bulbectomized rat model of depression.

Rapid onset of action in behavioral despair tests.

Rodent models used to screen antidepressant activity showed quick behavioral improvements.

05What is known vs. unknown

Reasonably established
  • Nemifitide is a synthetic pentapeptide analog of MIF-1.
  • It has demonstrated a rapid onset of antidepressant action, sometimes within 5 days.
  • It has been evaluated in Phase II/III clinical trials for major depressive disorder.
  • It is typically administered via subcutaneous injection.
Unknowns & limits
  • The exact mechanism of action in the central nervous system is not fully elucidated.
  • Long-term safety and efficacy data are limited compared to traditional antidepressants.
  • It has not received FDA approval for the treatment of depression.

06Safety & regulatory context

Regulatory statusNemifitide has been evaluated in clinical trials and generally showed a favorable safety profile, though common side effects may include injection site reactions, headache, and nausea. It is not FDA-approved for any medical condition and remains an investigational compound. Its use is restricted to research settings.

07Compared with MIF-1 (Melanocyte-inhibiting factor)

Nemifitide vs. MIF-1 (Melanocyte-inhibiting factor)
Key difference
Nemifitide is a synthetic pentapeptide analog designed for improved stability and efficacy compared to the endogenous tripeptide MIF-1.
When researchers discuss each
MIF-1 is discussed in the context of endogenous neuropeptide regulation, while Nemifitide is discussed as a targeted therapeutic candidate for rapid-acting depression treatment.

08Glossary

Pentapeptide
A peptide consisting of exactly five amino acids.
Melanocyte-inhibiting factor (MIF-1)
An endogenous peptide that modulates brain function and has been studied for its antidepressant properties.
Major Depressive Disorder (MDD)
A mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing significant impairment in daily life.

09Knowledge check

Q1What is the primary clinical application investigated for Nemifitide?
Q2Nemifitide is an analog of which endogenous peptide?
Q3Which statement best reflects a documented limitation in interpreting Nemifitide's long-term therapeutic potential?
Q4According to the dossier's comparison, how does Nemifitide differ from endogenous MIF-1?
Q5Which statement best summarizes Nemifitide's regulatory and safety status as described in the dossier?

10Sources

More in Cognitive Enhancement

See all

Semax

Cognitive Enhancement
Human clinical

Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH) that has been extensively studied for its neuroprotective and cognitive-enhancing properties. Research indicates it may modulate brain-derived neurotrophic factor (BDNF) and protect neurons from hypoxic damage, making it a subject of interest in stroke recovery and cognitive decline.

200-1000 mcg per day

Selank

Cognitive Enhancement
Human clinical

Selank is a synthetic heptapeptide analogue of the naturally occurring immunomodulatory peptide tuftsin. It has been extensively researched for its anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) properties, showing the ability to reduce stress and improve memory without the sedative side effects typical of traditional anti-anxiety medications.

250-500 mcg per day (often administered via nasal spray or SubQ)

Dihexa

Cognitive Enhancement
Preclinical only

Dihexa is an oligopeptide variant derived from angiotensin IV that binds to hepatocyte growth factor (HGF) and its receptor c-Met. Research in animal models suggests it has profound synaptogenic and neurogenic properties, showing potential for improving cognitive function and repairing brain damage in conditions like Alzheimer's disease and traumatic brain injury.

10-20 mg/day (oral/sublingual) or 2-5 mg/day (SubQ)
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.